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ABSTRACT
Despite intensive research, the physiology of the serological response to SARS-CoV-2 infection and its 
dynamics during the recovery period remain incompletely understood. Regulation of the immune response 
seems all the more important as it plays a role in both virus clearance during infection and the potential 
development of long-term resistance to reinfection. A case of convalescent plasma donor is described in 
whom was observed a prolonged enhanced immune response to infection in the form of a persistently high 
level of anti-Spike IgG despite subsequent plasma donations. The presented donor experienced COVID-19 
interstitial pneumonia, requiring pharmacotherapy in a hospital setting (therapy involving azithromycin, 
chloroquine and protease inhibitors), which allowed him to achieve remission. The described donor do-
nated plasma nine times during convalescence, each time showing a satisfactory level of anti-Spike IgG. 
The presented case highlights the multifactorial regulation of the serological response in the course of 
SARS-CoV-2 infection, which may include the long-term effect of pharmacotherapy, especially in the field 
of antiretroviral drugs. While the authors are not yet able to clearly define the importance of antiretroviral 
therapy in regulating the humoral response in COVID-19 patients, it is supposed it may be important in 
the subsequent antibody production.
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The SARS-CoV-2 virus, which is the cause of the 
global pandemic, is the subject of intense research in-
volving almost the entire world of science. Many aspects 
of viral biology remain unknown, including the physi-
ology of the serological response to infection and the 
mechanisms regulating its severity in both asymptom-
atic and symptomatic (including those developing the 
COVID-19 disease) patients [1]. Understanding the reg-
ulation of the immune response as a reaction to SARS-
CoV-2 infection seems to be all the more important as 
it plays a role in both viral clearances during infection 
and the potential development of long-term immunity 
to reinfection. While the half-life of anti-SARS-CoV-2 IgG 
antibodies has been determined to be around 36 days 
[2], due to the relatively short time of observation of the 
virus, determining the overall duration of the immune 
response is not possible yet. It is worth noting that the 
key elements in the long-term response to infection 
are ultimately differentiated B-cell lines, known as 
antibody-secreting cells (ASCs), which determine the 
humoral immune response and mechanisms that regu-
late their function [1]. An extremely important issue here 
seems to be the directing of the B-cell differentiation pro-
cess towards long-lived or short-lived plasma cells [3], 
which may determine resistance to reinfection or be no 
less important in the context of obtaining convalescent 
plasma for the needs of later transfusions. It should also 
be assumed that further understanding of the immune 
response also requires an evaluation of the influence 
of pharmacotherapy on the modulation of the immune 
response, both during an ongoing infection and upon 
extinction of the immune response, understood as the 
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recovery phase. A case report of a man with a history 
of SARS-CoV-2 infection is presented, complicated by 
COVID-19 interstitial pneumonia, in whom was observed 
a prolonged enhanced immune response to infection 
in the form of a persistently high level of anti-SARS-
CoV-2 antibodies in the IgG class despite subsequent 
plasma donations.
Case report
A 52-year-old man came to the facility for a conva-
lescent plasma (CCP) donation having been previously 
infected with the SARS-CoV-2 virus, complicated by 
the development of COVID-19 interstitial pneumonia, 
requiring hospitalization in the Department of Infectious 
Diseases. The diagnosis was made based on a positive 
real-time PCR test (nasopharyngeal swab taken on 
March 30th, 2020) and the presence of characteristic 
clinical symptoms (fever > 38°C and cough, which 
appeared 3 days after returning from a trip to Georgia). 
In the laboratory tests performed on admission to the 
hospital, apart from an increased concentration of 
C-reactive protein (CRP) (14.25 mg/L, normal range: 
0.00–5.00 mg/L) and an increased level of D-Dimer 
(907.00 ng/mL, normal range: < 500 ng/mL), no 
significant laboratory abnormalities were found. The 
complete blood count was within the normal range 
and the parameters of the white blood cell differential 
count were as follows: WBC 4.45 x 103/mL; NEU 2.92 
x 103/mL; LYMP 1.04 x 103/mL, MONO 0.46 x 103/mL, 
EO 0.01 x 103/mL; BASO 0.01 x 103/mL. After the initial 
stage, during which only febrile episodes and persistent 
cough were observed, the patient’s general condition 
deteriorated with the development of dyspnoea requir-
ing passive oxygen therapy and interstitial pneumonia, 
confirmed by a CT scan of the chest. For this reason, 
treatment with a macrolide antibiotic (azithromycin) was 
initiated. Due to increasing values  of the inflammatory 
markers (CRP 40.39 mg/L), deterioration of the patient’s 
clinical condition and progression of changes in the 
radiological image (appearance of new lesions with 
morphology characteristic of COVID-19 pneumonia), 
antiretroviral therapy (protease inhibitors combina-
tion - lopinavir/ritonavir) and chloroquine were added 
to the pharmacological treatment in an attempt to 
reverse disease progression. In the following days 
of hospitalization, improvement in the clinical condi-
tion, a decrease in the concentration of inflammatory 
markers and gradual disappearance of changes in 
the radiological image were observed. Analysing the 
clinical course and the results of laboratory and imag-
ing tests, the course of the disease was classified as 
moderate, based on the developed guidelines for the 
management of COVID-19 [4]. At discharge from the 
hospital, the white blood cell differential count present-
ed as follows: WBC 5.62 x 103/mL; NEU 2.91 x 103/mL; 
LYMP 1.92 x 103/mL, MONO 0.63 x 103/mL, EO 0.11 
x 103/mL; BASO 0.03 x 103/mL. After nearly four weeks 
of hospitalization, the patient was discharged home in 
good general condition.    
On April 30, 2020, five weeks after obtaining a pos-
itive (+) PCR test for SARS-CoV-2 virus RNA and two 
weeks after the last negative (–) PCR test for SARS-
CoV-2 virus RNA, the said donor reported to the facility 
for the first time. Following the qualification procedure, 
in line with the European Commission’s convalescent 
plasma collection and transfusion program [5], 750 mL 
of plasma was collected using an automated plasma-
pheresis system. No adverse reactions were observed 
during and after plasmapheresis. In total, nine plasma 
donations were obtained over four months, at varying 
intervals, dictated by the work schedule of the donor. 
In samples taken before each plasma donation, the 
levels of IgG anti-SARS-CoV-2 antibodies against Spike 
S1 (Euroimmun, USA), Spike S1/S2 (DiaSorin, Italy) 
and S-RBD domain (Snibe, China) were determined 
using the enzyme-linked immunosorbent assay (Spike 
S1) and chemiluminescent immunoassays (Spike 
S1/S2 and S-RBD domain). According to the manu-
facturer’s recommendations, the result was consid-
ered positive for the following test values: Euroimmun 
S1 IgG ≥ 1.1 [S/Co]; Diasorin S1 / S2 IgG ≥ 15 [AU/mL]; 
Snibe S-RBD IgG ≥ 1.0 [AU/mL].
Even though the determination of IgG antibodies 
against the S1 antigen of the SARS-CoV-2 virus indi-
cates significant dynamics of decrease in the level of 
antibodies over time, the determination of IgG antibod-
ies against the S1/S2 antigens and S-RBD domain of 
the virus showed much lower dynamics of decrease. 
Based on the observations of the described donor, it 
can be concluded that the time between confirmation 
of the infection in the PCR-RNA test and the moment 
when the antibody test is still positive amounts to 
157 days.
Importantly, in each of the anti-SARS-CoV-2 S1/S2 an-
tibody determinations, the antibody concentration val-
ues remained above 80 AU/mL, which, according to 
the available literature data [6], seems to correlate with 
the satisfactory level of neutralizing antibodies (nAbs). 
Also, concerning the anti-S-RBD antibodies, a strong 
correlation was demonstrated with the titre of neutral-
izing antibodies [7]. These observations are all the 
more valuable as conducting tests for the presence of 
neutralizing antibodies is time-consuming and involves 
several complicated procedures, such as providing 
a laboratory with a high microbiological safety class, 
which limits the implementation of this kind of tests by 
several institutions. The obtained results are presented 
in Figure 1.




















   Precentage of the baseline IgG S1/S2
100,00% 78,43% 92,81% 72,55% 87,58% 80,39% 75,16% 66,67% 62,75%
   Precentage of the baseline IgG S-RBD
100,00% 88,86% 81,69% 70,24% 64,84% 59,32% 57,69% 49,34% 48,84%
   Precentage of the baseline IgG S1
100,00% 95,39% 91,07% 85,24% 81,30% 79,98% 61,75% 49,06% 45,02%
   S1/S2 IgG [AU/mL] 153,00 120,00 142,00 111,00 134,00 123,00 115,00 102,00 96,00
   S-RBD IgG [AU/mL] 81,45 72,38 66,54 57,21 52,81 48,32 46,99 40,19 39,78


















The presented case suggests that one should not 
forget about possible immunomodulation related to 
the applied pharmacotherapy while analysing the hu-
moral response in the course of SARS-CoV-2 infection. 
Patients whose course of the disease is classified as 
moderate or severe deserve special attention as it is 
then that the pharmacotherapy that interferes with the 
immune system is used to eliminate the virus or stop its 
intracellular penetration, but also for fear of developing 
a “cytokine storm”. According to the literature, the azith-
romycin and chloroquine used in this case are associ-
ated primarily with suppression of the immune system, 
including control of the production of pro-inflammatory 
cytokines such as IL-1 and IL-6 [8]. Direct evidence 
for the role of drug-induced immunomodulation was 
provided by studies involving the murine vaccination 
model, which showed that prior azithromycin therapy 
led to a significant reduction in the primary humoral 
response during pneumococcal vaccination [9]. Con-
cerning proteasome inhibitors, the situation is much 
more complex as they both have a suppressive effect 
on selected proinflammatory cytokines, being at the 
same time also characterized by an ability to stimulate 
T-cell proliferation, which is the most desirable action in 
their primary indication - HIV infection. Importantly, it has 
been proved that antiretroviral therapy also significantly 
affects the proliferation and function of B cells, enhanc-
ing the humoral response to both HIV and non-HIV 
antigens [10]. Although the authors do realize that it is 
extremely important in obtaining an appropriate immune 
response during immunization in HIV positive patients 
[10], they are not yet able to define the significance of 
this interference with the immune system in the context 
of COVID-19 patients treated with antiretroviral therapy.
Conclusion
Although a long-term donor follow-up was conduct-
ed, the observations are limited due to single-subject 
analysis, which makes it difficult to draw firm conclu-
sions. The authors are aware that much more cases 
are needed to support the presented hypothesis and 
findings. Nevertheless, the presented report shows the 
Figure 1. The level of anti-Spike IgG antibodies in subsequent convalescent plasma donations
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multifactorial regulation of the serological response in 
the course of the SARS-CoV-2 infection, the under-
standing of which seems to be crucial in the further 
fight against the ongoing pandemic.
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